Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q9RR
|
|||
| Former ID |
DCL000450
|
|||
| Drug Name |
AZD0328
|
|||
| Synonyms |
AR-R23465XX; AZD-0328; Spiro[1-azabicyclo[2.2.2]octane-8,8'-7-oxa-5-azabicyclo[4.3.0]nona-2,4,10-triene]
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Discontinued in Phase 2 | [1], [2] | |
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H16N2O
|
|||
| Canonical SMILES |
C1CN2CCC1C3(C2)CC4=C(O3)N=CC=C4
|
|||
| InChI |
1S/C13H16N2O/c1-2-10-8-13(16-12(10)14-5-1)9-15-6-3-11(13)4-7-15/h1-2,5,11H,3-4,6-9H2/t13-/m0/s1
|
|||
| InChIKey |
OCKIPDMKGPYYJS-ZDUSSCGKSA-N
|
|||
| CAS Number |
CAS 220099-91-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neuronal acetylcholine receptor alpha-7 (CHRNA7) | Target Info | Modulator | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Cholinergic synapse | ||||
| Nicotine addiction | ||||
| Chemical carcinogenesis | ||||
| Panther Pathway | Alzheimer disease-amyloid secretase pathway | |||
| Nicotinic acetylcholine receptor signaling pathway | ||||
| Reactome | Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | |||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7697). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018503) | |||
| REF 3 | Ultra-low exposure to -7 nicotinic acetylcholine receptor partial agonists elicits an improvement in cognition that corresponds with an increase in -7 receptor expression in rodents: implications for low dose clinical efficacy.Neuroscience.2011 Jul 14;186:76-87. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.